LCM
AZN icon

Laurion Capital Management’s AstraZeneca AZN Stock Holding History

Laurion Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,500
Closed -$852K – 1546
2017
Q2 		$852K Buy
+12,500
New +$816K ﹤0.01% 1080

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Laurion Capital Management's AZN Position: Q1 2026 in Review

Laurion Capital Management held its AstraZeneca (AZN) position steady in Q1 2026 at 9,500 shares worth $1.87M. The position accounts for 0.08% of the portfolio, ranked #219.

Laurion Capital Management first reported a position in AZN in Q2 2017 and has held it in 10 quarters since. The position peaked at $23.9M in Q2 2017. 1,380 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Laurion Capital Management held 9,500 shares of AstraZeneca worth $1.87M as of Q1 2026.
  • Laurion Capital Management left its AstraZeneca share count unchanged in Q1 2026.
  • AstraZeneca made up 0.08% of Laurion Capital Management's portfolio in Q1 2026, its #219 holding.
  • Laurion Capital Management first reported a position in AstraZeneca in Q2 2017 and has held it in 10 quarters since.
  • Laurion Capital Management's AstraZeneca position peaked at $23.9M in Q2 2017.
  • 1,380 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.